Facebook Inc (NASDAQ:FB) shares fell 2.66% in pre-market trading to $94.33 despite beating Q2 earnings expectations. Facebook posted earnings of $0.50 per share on $4.04 billion in revenue, beating the Street’s expectations of $0.47 per share and $3.99 billion in revenue. Earnings per share and revenue increased 19% and 39% year-over-year, respectively. Facebook’s quarterly costs and expenses also increased to $2.76 billion, up from $1.5 billion in the same quarter a year prior. Facebook has warned investors of increased R&D spending in 2015 in an effort to focus on developing new technologies. As a result, operating margin dropped to 31% from 48% in Q2 2014. According to the 24 analysts polled by TipRanks in the last 3 months, 23 are bullish on Facebook and 1 is bearish. The average 12-month price target for Facebook is $106.09, marking a 9.38% potential upside from where the stock last closed.
Nokia Corporation (ADR) (NYSE:NOK) shares jumped 5.92% in pre-market trading to $6.98 after the company released an interim report for Q2 2015 and January-June 2015 before the opening bell on July 30. The company posted earnings of $0.10 a share on $3.54 billion in revenue. Nokia Networks net sales jumped 6% from the same quarter a year prior. Non-IFRS gross profits rose 12% year-over-year and gross margin for Nokia Networks grew by 40% as a result of higher software sales. Net sales for Nokia’s technology segment increased 31% and its non-IFRS operating profit increased 17% driven by higher patent licensing fees. According to 4 analysts polled by TipRanks in the last 3 months, 1 analyst is bullish on Nokia Corporation and 3 are neutral. The average 12-month price target for Nokia Corporation is $9.00, marking a 36.57% potential upside from where the stock last closed.
Synergy Pharmaceuticals Inc (NASDAQ:SGYP) shares soared over 18% in pre-market trading up to $9.69 after the company announced positive trial results for its pipeline drug, plecanatide, which aims to treat patients with chronic idiopathic constipation. The second of pivotal phase 3 trial assessed the safety and efficacy of two different doses of the drug. Preliminary data suggests that both doses met the primary endpoint of the study with statistical significance. Both doses proved to be safe and well-tolerated in patients, with the most common side effect being diarrhea. Synergy plans to file a New Drug Application for the drug in January 2016. According to the 2 analysts polled by TipRanks in the last 3 months, both are bullish on the stock. The average 12-month price target for SGYP is $16.50, marking a 100% potential upside from where the stock last closed.
Stratasys, Ltd. (NASDAQ:SSYS) plummeted more than -22% in pre-market trading to $28.25 after the 3D printing company posted second quarter losses. Stratasys posted a GAAP net of ($0.55) per diluted shares, missing the analyst consensus of $0.15 by a long shot and marking a stark drop from the ($0.00) per diluted share the company posted in the same quarter of last year. The company posted revenue of $182.3 million, in-line with analyst estimates but relatively flat to the $178.5 million the company posted in the same quarter of last year. Overall, shares of the company have been falling all year and are now trading near the company’s 52-week low of $30.95, down from the 52-week high of $37.54. According the 10 analysts polled by TipRanks in the last 3 months, 5 are bullish on SSYS and 5 are neutral. The average 12-month price target on the stock is $44.33, marking a potential upside 21% from where the stock last closed.